Cancer drug pelabresib gets Long-Term safety check in extension trial
NCT ID NCT06401356
First seen Jun 16, 2026 · Last updated Jun 16, 2026
Summary
This study looks at the long-term safety and benefits of the drug pelabresib in people with blood cancers, solid tumors, or advanced cancers. It includes up to 50 adults who were in earlier pelabresib studies and are still benefiting from the drug. Some participants who received placebo or stopped pelabresib may also join to track survival over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic Jacksonville
RECRUITINGJacksonville, Florida, 32224, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mt Sinai Medical Center
RECRUITINGNew York, New York, 10029-6574, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
New York Presbyterian Hospital
RECRUITINGNew York, New York, 10021, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novartis Investigative Site
RECRUITINGAntwerp, 2030, Belgium
-
Novartis Investigative Site
RECRUITINGBruges, 8000, Belgium
-
Novartis Investigative Site
RECRUITINGFlorence, FI, 50134, Italy
-
Novartis Investigative Site
RECRUITINGVarese, VA, 21100, Italy
-
Novartis Investigative Site
RECRUITINGNovara, 28100, Italy
-
Novartis Investigative Site
RECRUITINGAmsterdam, 1081, Netherlands
-
Novartis Investigative Site
RECRUITINGCardiff, CF14 4XW, United Kingdom
-
Novartis Investigative Site
RECRUITINGGlasgow, G12 0YN, United Kingdom
-
Novartis Investigative Site
RECRUITINGLondon, SE1 7EH, United Kingdom
-
Uni Of Michigan Health System
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Email: •••••@•••••
Contact
-
University of California LA
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.